1. Home
  2. FIZZ vs KOD Comparison

FIZZ vs KOD Comparison

Compare FIZZ & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Beverage Corp.

FIZZ

National Beverage Corp.

HOLD

Current Price

$34.41

Market Cap

3.2B

ML Signal

HOLD

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

HOLD

Current Price

$42.35

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIZZ
KOD
Founded
1985
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.8B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
FIZZ
KOD
Price
$34.41
$42.35
Analyst Decision
Strong Sell
Buy
Analyst Count
1
7
Target Price
$35.00
$35.43
AVG Volume (30 Days)
162.8K
692.0K
Earning Date
03-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
5.29
N/A
EPS
1.53
N/A
Revenue
$1,201,354,000.00
N/A
Revenue This Year
$0.14
N/A
Revenue Next Year
$3.33
N/A
P/E Ratio
$22.31
N/A
Revenue Growth
0.81
N/A
52 Week Low
$31.21
$3.33
52 Week High
$47.88
$47.84

Technical Indicators

Market Signals
Indicator
FIZZ
KOD
Relative Strength Index (RSI) 52.59 54.05
Support Level $32.58 $39.37
Resistance Level $35.86 $46.72
Average True Range (ATR) 0.73 3.05
MACD 0.09 -0.81
Stochastic Oscillator 64.09 35.41

Price Performance

Historical Comparison
FIZZ
KOD

About FIZZ National Beverage Corp.

National Beverage Corp is a non-alcoholic beverage company in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls the majority of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for retailers, direct-store delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants).

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: